Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Thymosin Alpha1

Phase 3Small molecule

SSun Yat-sen University

Thymosin Alpha1 is one of 134 small molecule programs targeting NSCLC. It is currently in Phase 3.

5

Indications

9

Total Trials

4

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLCRecruiting

SepsisActive, not recruiting

Rheumatic Heart DiseaseActive, not recruiting

Recurrent Implantation FaliureRecruiting

Colorectal CancerRecruiting

NSCLCPreclinical

Recruiting

SepsisPreclinical

Active, not recruiting

Rheumatic Heart DiseasePreclinical

Active, not recruiting

Recurrent Implantation FaliurePreclinical

Recruiting

Colorectal CancerPhase 3

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Telisotuzumab Adizutecan

XL092

TAS 102

Taiho Oncology, Inc.

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

5-Fu

TToray Industries, Inc

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Thymosin Alpha1

SSun Yat-sen University

TQB2102

CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Leucovorin and 5-FU

HR070803

JJiangsu HengRui Medicine Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Not yet recruiting

Sepsis

NCT04901104

Phase 3Recruiting

Colorectal Cancer

NCT05086614

Q2 2027

PreclinicalRecruiting

Recurrent Implantation Faliure

NCT07675980

Clinical

Trials by Indication[1]

Sepsis1 trial

Long-term Prognosis of Patients With Sepsis After Immunotherapy

Not yet recruiting·SSun Yat-sen University··NCT04901104·900 enrolled

NSCLC1 trial

Immuno-effect of Tα1 for Stage I NSCLC

Recruiting·YYousheng Mao·N/A·NCT06598839·40 enrolled

Colorectal Cancer1 trial

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Recruiting·FFudan University·Phase 3·NCT05086614·2,500 enrolled

IrAE1 trial

Thymosin Alpha-1 for irAE Secondary to ICIs

Unknown status·JJun Wang·Phase 4·NCT06178146·40 enrolled

Elderly Patients1 trial

Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain

Unknown status·RRenJi Hospital·Phase 4·NCT04524169·100 enrolled

4 more indications

Combination Therapy1 trial

Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients

Unknown status·WWen-hong Zhang·Phase 4·NCT03448744·240 enrolled

Rheumatic Heart Disease1 trial

Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass

Unknown status·NNanjing Medical University·N/A·NCT05487469·200 enrolled

Non-Small Cell Lung Cancer1 trial

A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer

Completed·SSun Yat-sen University·Phase 2·NCT06139419·114 enrolled

Recurrent Implantation Faliure1 trial

Thymosin-α1 for Recurrent Implantation Failure Following Transfer of PGT-a Tested Embryo: A Randomized, Double-Blind, Placebo-Controlled Trial

Recruiting·FFakih IVF Fertility Center·Preclinical·NCT07675980·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Thymosin Alpha1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thymosin Alpha1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thymosin Alpha1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSun Yat-sen University

Related News